| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | Recombinant full-length human ALPP protein was used as the immunogen for the Placental Alkaline Phosphatase antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
Placental Alkaline Phosphatase Antibody is a research-use primary antibody intended for detection of PLACENTAL in experimental workflows. It is supplied in Purified format. Key antibody attributes include Mouse, Monoclonal (mouse origin), clone ALPP/238, isotype Mouse IgG2a, kappa. Applications listed for this product include ELISA. Reported/annotated localization context: Cytoplasmic and cell surface. Species reactivity (as provided): Human.
Key elements and design rationale
- Target: PLACENTAL (Placental Alkaline Phosphatase) — selectivity and interpretation should be considered in the context of isoforms, post-translational modifications, and related family members when applicable.
- Format: Purified — format can influence background, multiplexing compatibility, and downstream detection strategies.
- Antibody identity: Mouse, Monoclonal (mouse origin), clone ALPP/238, isotype Mouse IgG2a, kappa — these attributes help align secondary reagents and controls (e.g., isotype-matched controls) with your assay design.
- Localization: Cytoplasmic and cell surface — expected subcellular distribution can guide band/structure interpretation and help flag off-target signal.
- Product notes (from provided description): PLAP is a tissue specific, trophoblast-derived, 70kDa, glycosyl-phosphatidylinositol (GPI)-anchored, dimeric, Zn2+ metallo glycoprotein that catalyzes the hydrolysis of phosphomonoesters into an inorganic phosphate and an alcohol. It is present in the placenta and serum of pregnant women and in high frequency in gynecological and testicular cancers and in lower frequency in other tumors. The three tissue-specific AP's in humans, PLAP, germ cell AP (GCAP) and intestinal AP, are 90-98% homologous. Non-tissue specific AP is found in kidney, liver and bone. This mAb binds equally well to all common allelic variants (S, F, FS and I) of PLAP as to AP from normal human testis. This mAb can be used both as coating as well as tracer antibody in the same ELISA to detect PLAP in serum of S, F, FS and I phenotypes.
Where multiple assay formats are possible, align the antibody format, host/isotype, and listed applications with your detection system and controls to support clear interpretation of signal.
Biological background
In this catalog, PLACENTAL is positioned within Renal & Urology, Cancer, Tumor, Kidney disease research contexts. Localization annotations (e.g., Cytoplasmic and cell surface) can help contextualize expected signal patterns in imaging and fractionation-based readouts. For authoritative gene/protein nomenclature, domains/isoforms, and curated functional annotations, consult resources such as UniProt, NCBI Gene, and Ensembl.
Research relevance and current trends
- Higher-plex and spatially resolved readouts (e.g., multiplex IF/IHC, spatial omics) are increasing demand for well-characterized primary antibodies with clearly stated host/isotype and labeling strategies.
- Genetic perturbation controls (knockout/knockdown) and orthogonal measurements (e.g., RNA vs protein) are commonly used to strengthen target attribution when interpreting antibody-derived signals.
- Reproducibility initiatives emphasize transparent reporting of antibody identity (clone, host, isotype) and experimental context to improve cross-study comparability.
Common research applications
- ELISA: interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform/PTM differences across conditions.
- Typical workflow themes: ELISA binding assay, Specificity controls, Antibody titration.
- Workflow notes: Measure binding to PLACENTALALKALI peptide/protein by ELISA with dilution series (include blanks), Confirm specificity using KO/KD or peptide competition controls in your primary assay, Optimize antibody dilution acro…
When comparing conditions, consistent sample processing and appropriate negative/positive controls support interpretation of qualitative localization differences and quantitative abundance changes.
Notes for experimental interpretation
- Isoforms and post-translational modifications may shift apparent molecular weight or epitope accessibility, especially across cell states or treatments.
- Species and tissue context can affect sequence conservation, expression level, and background binding; predicted reactivity should be verified in your sample.
- Control concepts include isotype-matched controls, secondary-only controls (for indirect detection), and genetic/orthogonal controls (e.g., KO/KD, independent antibodies, or RNA measurements) when feasible.
Monoclonal and polyclonal antibodies can differ in epitope recognition breadth and lot-to-lot characteristics; consider clonality and clone information (when provided) alongside your assay requirements. Conjugated formats may simplify detection but can change background and multiplexing behavior compared with unconjugated primaries.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
